The Hemoglobin A1c Level as a Progressive Risk Factor for Cardiovascular Death, Hospitalization for Heart Failure, or Death in Patients With Chronic Heart Failure.

The article presents a study which examines the role of hemoglobin A1c levels as progressive risk factors for cardiovascular (CV) events in patients with symptomatic chronic heart failure (HF). The study focused on participants of the Candesartan in Heart Failure: Assessment of Reduction in Mortality and Morbidity (CHARM) program. An analysis of the incidence of cardiovascular death, hospitalization for heart failure and total mortality in patients with chronic heart failure was also conducted.